Iwai, T., Sugimoto, M., Harada, S., Yorozu, K., Kurasawa, M., & Yamamoto, K. (2016). Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. Oncol Rep.

Iwai, Toshiki, Masamichi Sugimoto, Suguru Harada, Keigo Yorozu, Mitsue Kurasawa, and Kaname Yamamoto. "Continuous Administration of Bevacizumab Plus Capecitabine, Even After Acquired Resistance to Bevacizumab, Restored Anti-angiogenic and Antitumor Effect in a Human Colorectal Cancer Xenograft Model." Oncol Rep 2016.

Iwai, Toshiki, et al. "Continuous Administration of Bevacizumab Plus Capecitabine, Even After Acquired Resistance to Bevacizumab, Restored Anti-angiogenic and Antitumor Effect in a Human Colorectal Cancer Xenograft Model." Oncol Rep 2016.